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Stress and glucocorticoid hormones regulate hippocampal neurogenesis, but the molecular mechanisms underlying their effects are
unknown. We, therefore, investigated the molecular signaling pathways mediating the effects of cortisol on proliferation, neuronal
differentiation, and astrogliogenesis, in an immortalized human hippocampal progenitor cell line. In addition, we examined the molecular
signaling pathways activated in the hippocampus of prenatally stressed rats, characterized by persistently elevated glucocorticoid levels in
adulthood. In human hippocampal progenitor cells, we found that low concentrations of cortisol (100 nM) increased proliferation
(þ 16%), decreased neurogenesis into microtubule-associated protein 2 (MAP2)-positive neurons ( 24%) and doublecortin (Dcx)-
positive neuroblasts ( 21%), and increased differentiation into S100b-positive astrocytes (þ 23%). These effects were dependent on
the mineralocorticoid receptor (MR) as they were abolished by the MR antagonist, spironolactone, and mimicked by the MR-agonist,
aldosterone. In contrast, high concentrations of cortisol (100 mM) decreased proliferation ( 17%) and neuronal differentiation into
MAP2-positive neurons ( 22%) and into Dcx-positive neuroblasts ( 27%), without regulating astrogliogenesis. These effects were
dependent on the glucocorticoid receptor (GR), blocked by the GR antagonist RU486, and mimicked by the GR-agonist,
dexamethasone. Gene expression microarray and pathway analysis showed that the low concentration of cortisol enhances Notch/Hes-
signaling, the high concentration inhibits TGFb-SMAD2/3-signaling, and both concentrations inhibit Hedgehog signaling. Mechanistically,
we show that reduced Hedgehog signaling indeed critically contributes to the cortisol-induced reduction in neuronal differentiation.
Accordingly, TGFb-SMAD2/3 and Hedgehog signaling were also inhibited in the hippocampus of adult prenatally stressed rats with high
glucocorticoid levels. In conclusion, our data demonstrate novel molecular signaling pathways that are regulated by glucocorticoids in vitro,
in human hippocampal progenitor cells, and by stress in vivo, in the rat hippocampus.
Neuropsychopharmacology (2013) 38, 872–883; doi:10.1038/npp.2012.253; published online 16 January 2013
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INTRODUCTION
The molecular signaling mechanisms by which glucocorti-
coid hormones regulate hippocampal neurogenesis are
unknown. Stress increases circulating levels of endogenous
glucocorticoids (Pariante and Lightman, 2008; Anacker
et al, 2011a), which in turn decrease adult hippocampal
neurogenesis (David et al, 2009; Anacker et al, 2011b; Gould
et al, 1991; Surget et al, 2011). Importantly, impaired
hippocampal neurogenesis in rodents has recently been
shown to contribute to the development of depressive
symptoms in response to stress (Snyder et al, 2011),
suggesting that the glucocorticoid-induced reduction in
neurogenesis may indeed contribute to the pathogenesis of
major depression. Discovering the molecular signaling
pathways by which glucocorticoids regulate hippocampal
neurogenesis is, therefore, crucial to indentify potential
targets for novel antidepressant treatments that counteract
stress-induced neurobiological abnormalities.
Endogenous glucocorticoids (cortisol in humans and
corticosterone (CORT) in rodents) act on two intracellular
receptors: the mineralocorticoid receptor (MR), which has
high affinity for endogenous glucocorticoids and is already
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activated by low, basal cortisol concentrations; and the
glucocorticoid receptor (GR), which has low affinity for
cortisol and is thus predominantly activated by high cortisol
concentrations, as they occur upon stress and in depression
(Anacker et al, 2011a; Pariante et al, 2008; Pariante and
Miller, 2001). We and others have demonstrated that stress
and GR activation consistently decrease hippocampal
neurogenesis in vitro and in vivo (Anacker et al, 2011b;
Kim et al, 2004; Fujioka et al, 2006; Gould et al, 1991; Mayer
et al, 2006; David et al, 2009). In contrast, the role of the MR
in neurogenesis is less clear, as some studies have reported a
decrease in proliferation upon MR activation (Wong and
Herbert, 2006; Montaron et al, 2003), while others have
found an increase (Fischer et al, 2002; Gass et al, 2000).
Previous studies have investigated candidate genes involved
in the stress- and glucocorticoid-induced reduction in
neurogenesis (Datson et al, 2010; Sippel et al, 2009; Xi
et al, 2010; Matrisciano et al, 2011). However, a complete
analysis of the intricate signaling mechanisms that mediate
the effects of glucocorticoids on the hippocampus is
lacking.
To address this issue, we have first analyzed the effects of
low (ie, MR-related) and high (GR-related) cortisol
concentrations on an immortalized human hippocampal
progenitor cell line, our established in vitromodel of human
neurogenesis in which we can determine the state of
proliferation and neuronal differentiation by the addition
and removal of growth factors (Anacker et al, 2011b;
Zunszain et al, 2011). Using pharmacological agonists and
antagonists for the MR and the GR, in combination with
immunocytochemistry and whole genome expression ana-
lysis, we have dissected MR- and GR-mediated regulation of
neurogenesis and astrogliogenesis. We have then conducted
whole genome expression analysis of the rat hippocampus
in animals subjected to prenatal stress, a well established
animal model of depression in which glucocorticoid levels
are elevated and hippocampal neurogenesis is decreased
(Lemaire et al, 2000; Fumagalli et al, 2007). Our study
reveals novel molecular signaling pathways regulated
consistently by cortisol in human hippocampal progenitor
cells and by stress in the rat hippocampus.
MATERIALS AND METHODS
Cell Culture
The immortalized, multipotent human fetal hippocampal
progenitor cell line HPC03A/07 (provided by ReNeuron Ltd,
UK) was used for all experiments (Anacker et al, 2011b).
HPC03A/07 cells proliferate in the presence of growth
factors (EGF, FGF) and 4-hydroxytamoxifen (4-OHT), while
differentiation is initiated upon growth factor and 4-OHT
removal. Detailed information on this cell line and culture
conditions can be found in the Supplementary Materials.
Drugs
All drugs and reagents were purchased from Sigma-Aldrich
(St Louis, MO) unless otherwise stated. Growth factors EGF
and bFGF were purchased from Peprotech (London, UK).
Purmorphamine was from Millipore, UK. Aldosterone,
dexamethasone, hydrocortisone, RU486 and spironolactone
were dissolved in 100% ethanol. Purmorphamine was
dissolved in 100% DMSO. Bromodeoxyuridine (BrdU) was
dissolved in phosphate-buffered saline fresh before use.
Proliferation Assay
Progenitor cell proliferation was assessed as previously
described (Anacker et al, 2011b) Briefly, HPC03A/07 cells
were plated on 96-well plates (Nunclon, Roskilde, Denmark)
at a density of 1.2 104 cells per well and cultured for 72 h
in the presence of growth factors and 4-OHT to maintain
proliferation. The synthetic nucleotide 50-BrdU, 10 mM) was
added to the media 4 h before treatment cessation. Cells
were fixed with 4% paraformaldehyde for 20min at room-
temperature.
Differentiation Assay
Differentiation was assessed as previously described
(Anacker et al, 2011b). Briefly, cells were cultured in the
presence of growth factors and 4-OHT for 3 days, and
subsequently washed and cultured in media without growth
factors and 4-OHT for further 7 days to allow differentia-
tion. For these experiments, cells were treated during the
initial proliferation phase and the subsequent differentia-
tion phase, or only during the proliferation phase, or only
during the differentiation phase. At the end of the total
incubation time (10 days) cells were fixed as described
above.
Immunocytochemistry
Proliferation was assessed by immunolabelling for BrdU
(rat anti-BrdU, Serotec, Oxford, UK). Differentiation into
young and mature neurons was assessed by immunocyto-
chemistry for Dcx (rabbit anti-Dcx, 1 : 1000, Abcam, Cam-
bridge, UK) and microtubule-associated protein-2 (MAP2)
(mouse anti-MAP-2[HM], 1 : 500, Abcam), respectively.
Astrogliogenesis was evaluated by immunocytochemistry
for S100 calcium-binding protein b (S100b) (rabbit anti-
S100b, 1 : 500, DAKO, Glostrup, Denmark). Synaptic mar-
kers were detected by staining for synaptophysin (mouse
anti-synaptophysin, 1 : 100, Assaydesigns) and Homer1
(rabbit anti-Homer1, 1 : 100, Synaptic Systems). Cells were
also stained for the hippocampal granule-cell-marker,
Prospero homeobox protein 1 (Prox1) (mouse anti-Prox1,
1 : 100, Abcam). Hoechst 33342 dye was used to label all
cells. The number of Dcx-, MAP2-, S100b- and BrdU-
positive cells over total Hoechst 33342-positive cells was
determined to assess neurogenesis, astrogliogenesis, and
progenitor proliferation (see Supplementary Materials).
GR Transactivation Assay
To measure GR transactivation in HPC03A/07 cells upon
cortisol treatment, nuclear protein extracts were obtained
using a commercially available nuclear extraction kit
(Active Motif, Rixensart, Belgium). GR binding to a
consensus glucocorticoid response element DNA sequence
was analyzed using the enzyme-linked immunosorbent
assay-based TransAM GR method (Active Motif), according
to the manufacturer’s instructions.
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Ethics Statement
All animal handling and experimental procedures were
performed in accordance with the EC (EEC Council
Directive 86/609 1987), the Italian legislation on animal
experimentation (Decreto Legislativo 116/92), and the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals. All efforts were made to minimize
animal suffering and to reduce the number of animals used.
Prenatal Stress Study
Nulliparous adult female (body weight 230–260 g) and male
(400 g) Sprague-Dawley rats were pair-housed with a same-
sex conspecific with food and water available ad libitum
(21±1 1C, 60±10% relative humidity, reversed 12/12 h
light/dark cycle). After 10 days, rats were mated for 24 h
and individually housed immediately thereafter. Pregnant
females were randomly assigned to delivery control (ctrl)
and prenatal stress (PNS) conditions. PNS consisted of
restraining pregnant dams in a transparent Plexiglas
cylinder (7.5 cm diameter, 19 cm length) under bright light
(6.500 l ) for 45min three times daily during the last week
of gestation. PNS sessions were separated by 2–3 h intervals
and conducted at varying periods of the day to reduce
habituation. Control rats were left undisturbed. Male
offspring from control and PNS groups were killed at
postnatal day (PND) 62 for whole hippocampal dissection
(n¼ 7 for each group) and trunk blood collection (n¼ 5 for
each group).
CORT Analysis
Upon killing, trunk blood samples were collected individu-
ally in potassium EDTA tubes (1.6mg EDTA/ml blood,
Sarstedt, Germany). CORT was measured using a commer-
cially available radioimmunoassay kit containing 125-
Iodine labeled CORT (MP Biomedicals, CA). Assay sensi-
tivity was 0.125mg/dl. Vials were counted for 2min in a
gamma-scintillation counter (Packard Minaxi Gamma
counter, Series 5000).
RNA Isolation, Microarray Processing, Quality Control
RNA of human progenitor cells and rat hippocampal tissue
was isolated using RNeasy mini kit (Qiagen, Crawley, UK)
and subsequently DNase treated (Ambion, Warrington,
UK). RNA was reverse transcribed using GeneAtlas 30IVT
Express Kit (Affymetrix, Santa Clara, CA).
Gene expression microarray assays were performed on
three independent experiments using Human Genome U219
Array Strips (for the gene expression analyses in cells) and
Rat Gene 1.1 T Array Strips (for the gene expression
analyses in rat) on the Affymetrix GeneAtlas platform
(http//www.affymetrix.com/support/technicalmanual/expres-
sion_manual_ affy). Partek Genomics Suite 6.6 software was
used for data visualization, statistical testing of affymetrix
CEL files and quality control. Data quality was assessed
using histograms of signal intensities, scatter plots, and
hierarchical clustering of samples. All samples passed the
criteria for hybridization controls, labeling controls and 30/
50 Metrics. Robust MultiChip Average method was used for
background correction and Quantiles normalization. Sum-
marization was performed using a median polish algorithm
(Tukey 1977) (see also Supplementary Materials).
Pathway Analysis
Pathway analysis for progenitor cells and hippocampi of
PNS rats was conducted with Pathway Studio Software 5.0
(Ariadne, Lausanne, Switzerland), using the standard Gene
Set enrichment analysis, originally developed by the Broad
Institute (http://www.broad.mit.edu/gsea/) (Mootha et al,
2003). This algorithm uses a correlation-weighted
Kolmogorov–Smirnov statistic on all gene expression
changes and computes pathway enrichment scores by
considering gene set membership information, gene list
ranking and gene–gene dependencies that reflect real
biology. We used Po0.005 as enrichment P-value cutoff
for pathway analysis in human hippocampal progenitor
cells, and Po0.05 as enrichment P-value cutoff for pathway
analysis in PNS rat hippocampi.
Quantitative Real-time PCR
RNA from human cells and rat hippocampal tissue was
reverse transcribed with Superscript III (Invitrogen) before
quantitative Real-Time PCR (qPCR) using the SYBR Green
method (Supplementary Materials).
Statistical Analysis
All statistical analyses for immunocytochemistry and qPCR
were performed with GraphPad Prism 4.03 (GraphPad, La
Jolla) on independent biological replicates (indicated as ‘n’).
One-way ANOVA with Newman-Keuls post hoc test was
used for multiple comparisons among the treatment groups.
Student’s t-test was used to compare means of two
independent treatment groups. P-valueso0.05 were con-
sidered significant. Data are presented as mean±s.e.m.
ANOVA was used in the gene expression microarray to
assess the effects of cortisol treatment on progenitor cells
and the effects of PNS in rats. To investigate the effects of
cortisol on progenitor cells, a three linear contrast was
performed using Partek Genomic Suite 6.6 (cortisol 100 nM
vs vehicle; cortisol 100 mM vs vehicle; cortisol 100 mM vs
cortisol 100 nM) with a maximum filter of Po0.05 and a
minimum absolute fold-change cutoff of 1.2. Genes that
passed these criteria were used to build up the Venn
diagram (Supplementary Figure 4a, Supplementary
Table 3). For both, cortisol-treated cells and adult PNS
rats, the cluster diagrams were built up using genes fulfilling
the criteria of Po0.01 and 1.2 minimum absolute fold-
change (Supplementary Tables 4 and 5; Supplementary
Figures 5 and 6).
RESULTS
Differential MR- and GR-dependent Effects of Cortisol
on Progenitor Cell Proliferation
We first analyzed the effects of a wide range of cortisol
concentrations (1 nM–100 mM) on proliferation of human
hippocampal progenitor cells after 3 days of treatment,
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using BrdU incorporation and immunocytochemistry
(Figure 1a).
Cortisol treatment showed dose-dependent, bimodal
effects on proliferation (One-way ANOVA, Po0.0001,
F1,7¼ 6.76, n¼ 4). Specifically, low concentrations (1 nM–
100 nM) increased proliferation (by 16% at 100 nM,
P¼ 0.002, n¼ 4; Figure 1b, third column), whereas high
concentrations (1 mM-100 mM) decreased proliferation (by -
17% at 100 mM, P¼ 0.002, n¼ 4; Figure 1b, last column). In
order to investigate whether MR and GR are involved in
these effects, we co-treated cells with cortisol (again 1 nM–
100 mM) and with the MR antagonist, spironolactone (1 mM),
or the GR antagonist, RU486 (50 nM). Spironolactone, but
not RU486, blocked the increase in proliferation upon
treatment with low cortisol concentrations (1 nM–100 nM),
indicating that this effect is mediated by the MR (Figure 1c).
Conversely, RU486, but not spironolactone, blocked the
decrease in proliferation upon treatment with high cortisol
concentrations (1 mM–100 mM) (Figure 1d), indicating that
this effect is mediated by the GR.
To confirm these findings, we also examined whether
MR- and GR-agonists would model the differential effects of
low- and high-cortisol concentrations on proliferation.
Indeed, the MR-agonist, aldosterone (1 nM–1 mM), increased
proliferation (One-way ANOVA, P¼ 0.02, F1,5¼ 3.27, n¼ 3;
Figure 1e), modeling the effects of low cortisol concentra-
tions. Moreover, the GR-agonist, dexamethasone (10 nM–
5 mM), decreased proliferation (One-way ANOVA,
Po0.0001, F1,5¼ 7.66, n¼ 3; Figure 1f), modeling the effects
of high cortisol concentrations and confirming our previous
data on decreased proliferation upon dexamethasone
treatment (1 mM) in the same model (Anacker et al, 2011b).
To further confirm that the higher cortisol concentrations
used in our study do not fully saturate the GR, we examined
GR transactivation upon cortisol treatment over a wider
range of concentrations (100 nM–2mM). In line with our
data on progenitor cell proliferation (described above), low
doses of cortisol (100 nM) did not significantly induce GR
binding to the DNA, while GR transactivation was dose-
dependently increased following higher cortisol concentrations
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Figure 1 Differential effects of mineralocorticoid receptor (MR)- and glucocorticoid receptor (GR)-activation on human hippocampal progenitor cell
proliferation. 50-bromodeoxyuridine (BrdU, 10mM) incorporation and immunocytochemistry was used to assess proliferation of HPC03A/07 cells (a).
Cortisol exerts bimodal, dose-dependent effects on proliferation (b). Spironolactone (1 mM) blocks the increase in cell proliferation upon treatment with low
concentrations of cortisol (c). RU486 (50 nM) blocks the decrease in cell proliferation upon treatment with high concentrations of cortisol (100 mM) (d). The
MR-agonist, aldosterone (1 nM–1 mM), increases cell proliferation (e), while the GR-agonist, dexamethasone (10 nM–5mM), decreases cell proliferation (f). GR
transactivation is dose-dependently increased by cortisol concentrations (10 mM–1mM) (g). Three to four independent experiments were conducted on
independent cultures (indicated as n). In proliferation experiments, four wells were analyzed per treatment condition in each experiment and three random,
non-overlapping pictures were analyzed for each well. All data are mean±s.e.m. *Po0.05, **Po0.01; ***Po0.001 compared with the vehicle-treated
control condition.
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(10 mM–2mM). Moreover, the concentration of 100 mM
cortisol did not saturate the GR, as transactivation could
be further increased by concentrations of up to 2mM
(Figure 1g). Concentrations of cortisol higher than 2mM
induced cell death.
MR- and GR-dependent Effects of Cortisol on
Differentiation into Neurons
To examine the effects of cortisol on neuronal differentia-
tion, cells were treated with two cortisol concentrations
selected for predominant MR activation (100 nM) or GR
activation (100 mM), as described above. Cells were cultured
for 3 days under proliferation conditions and subsequently
allowed to differentiate by removal of growth factors and 4-
OHT for subsequent 7 days. Immunocytochemistry for
MAP2 and Dcx was used to visualize mature neurons and
young neuroblasts, respectively (Figure 2a, top panels;
Supplementary Figure 1a).
When cells were treated only during the proliferation
phase (3 days) but not during the subsequent differentiation
phase (7 days), both cortisol concentrations decreased
neuronal differentiation. Specifically, the low concentration
(100 nM) decreased MAP2-positive neurons by  24%
(P¼ 0.005, n¼ 3; Figure 2b). As expected, this effect was
counteracted by the MR antagonist, spironolactone (1 mM),
and mimicked by the MR-agonist, aldosterone (1 mM)
( 21%, P¼ 0.01, n¼ 3; Figure 2b). Similar effects were
observed when we counted the number of Dcx-positive
neuroblasts (Supplementary Results, Supplementary
Figure 1b). The high cortisol concentration (100 mM) also
decreased MAP2-positive neurons by  22% (P¼ 0.002,
n¼ 3; Figure 2c). This effect was abolished by RU486
(50 nM), and mimicked by dexamethasone (1 mM) ( 27%,
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Figure 2 Low and high concentrations of cortisol exert differential MR- and GR-dependent effects on neurogenesis and astrogliogenesis.
Immunocytochemistry for microtubule-associated protein 2 (MAP2) and S100 calcium-binding protein b (S100) (a). If treated only during the proliferation
phase, the low cortisol concentration (100 nM) and aldosterone (1 mM) decrease the number of MAP2-positive neurons. Both effects are counteracted by
spironolactone (1mM) (b). The high cortisol concentration (100 mM) and dexamethasone (1mM) also decrease the number of MAP2-positive neurons. These
effects are both counteracted by RU486 (50 nM) (c). No effects on the number of MAP2-positive neurons are observed when cells are treated only during
the differentiation phase (d, e). the low cortisol concentration (100 nM) and aldosterone (1 mM) increase the number of S100b-positive astrocytes. Both
effects are counteracted by spironolactone (1mM) (f). The high cortisol concentration (100 mM) and dexamethasone (1mM) do not significantly alter the
number of S100b-positive astrocytes (g). No effects are observed on the number of S100b-positive astrocytes when cells are treated only during the
differentiation phase (h, i). Three independent experiments were conducted on independent cultures (n¼ 3). Four wells were analyzed per treatment
condition in each experiment and three random, non-overlapping pictures were analyzed for each well. All data are mean±s.e.m. *Po0.05, **Po0.01,
compared with the vehicle-treated control condition.
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P¼ 0.001, n¼ 3; Figure 2c). Again, similar effects were
observed when we counted the number of Dcx-positive
neuroblasts (Supplementary Results, Supplementary
Figure 1c). These data demonstrate that MR activation
and GR activation both decrease neuronal differentiation.
When cells were treated continuously during both, the
proliferation and the differentiation phase, we observed
similar effects on MAP2- and Dcx-positive cells
(Supplementary Results, Supplementary Figure 2a-d). In
contrast, treatment only during the differentiation phase, but
not during the preceding proliferation phase, did not exert
any significant effects (Figure 2d and e, Supplementary
Figure 1d and e), supporting the notion that MR- and GR-
activation during the proliferation phase is necessary and
sufficient to reduce neuronal differentiation.
All experiments above were conducted by allowing cells
to differentiate for 7 days. In order to elucidate whether
these newborn neurons continue to further develop into
hippocampal granule neurons that express synaptic mar-
kers, we analyzed the expression of synaptic markers and
hippocampal granule-cell markers after longer periods of
differentiation (5 weeks), when most cells have already fully
differentiated into MAP2-positive neurons. Indeed, differ-
entiated HPC03A/07 neurons express the synaptic markers,
synaptophysin and homer1, as well as the hippocampal
granule-cell-marker, Prox1 (Karalay et al, 2011)
(Supplementary Figure 3).
MR- and GR-dependent Effects of Cortisol on
Differentiation into Astrocytes
Next, we wanted to test whether the MR- and GR-mediated
decrease in neuronal differentiation, described above, is
associated with a cortisol-induced shift of progenitor cell
fate from neuronal- to astrocyte-differentiation. We thus
treated cells with cortisol and analyzed the number of
S100b-positive astrocytes (Figure 2a, bottom panels).
Treatment with the low cortisol concentration (100 nM)
and aldosterone (1 mM) only during the proliferation phase
increased the number of S100b-positive astrocytes (by 23%,
P¼ 0.003, n¼ 3; and by 20%, P¼ 0.004, respectively;
Figure 2f). Both effects were abolished by spironolactone
(1 mM) (Figure 2f). In contrast, the high cortisol concentra-
tion (100 mM) and dexamethasone (1 mM) did not change
the number of S100b-positive astrocytes (Figure 2g),
demonstrating for the first time that MR activation, but
not GR activation, induces astrocyte differentiation of
human hippocampal progenitor cells. However, when
interpreting our data it needs to be considered that the
high cortisol concentration also activates the MR (deKloet
and Derijk 2004). Notably, this high concentration induced
a small increase in S100b-positive astrocytes in the presence
of RU486 (Figure 2g, second column). Therefore, the lack of
effect suggests that predominant GR activation may inhibit
the MR-mediated increase in astrogliogenesis (as also
suggested by our pathway analysis, see below), resulting
in the net effect of no changes.
When cells were treated continuously during proliferation
and differentiation, similar effects on S100b-positive
astrocytes were observed (Supplementary Results,
Supplementary Figure 2e and f). Finally, and similar to
the effects on neuronal differentiation, treatment only
during the differentiation phase, but not during the
preceding proliferation phase, did not exert any significant
effects (Figure 2h and i), supporting the notion that MR
activation during the proliferation phase is necessary and
sufficient to induce astrogliogenesis.
Taken together, our results indicate that MR activation
increases hippocampal progenitor cell proliferation while
concomitantly shifting cell fate from neuronal- toward
astrocyte differentiation. In contrast, GR activation de-
creases proliferation and neuronal differentiation and
counteracts the MR-induced increase in astrogliogenesis.
Regulation of Molecular Signaling Pathways by Low and
High Cortisol Concentrations
Having discovered such profound effects of MR- and GR-
mediated cortisol action on hippocampal neurogenesis, we
wanted to establish the molecular signaling pathways
implicated in these effects. We focused specifically on the
signaling mechanisms during the proliferation phase, as
treatment during this phase was necessary and sufficient
to reduce neurogenesis and to increase astrogliogenesis,
as described above. We analyzed gene expression changes
after 12 hours of cortisol treatment, because our initial
real-time PCR analysis had shown the most significant
effects of cortisol on two selected glucocorticoid-regulated
genes (FKBP5, FOXO1) specifically at this time point
(Supplementary Figure 4). In this Results section we
present the results of the pathway analysis, as this
analysis best captures the complex signaling mechanisms
induced by low- and high-concentrations of cortisol
(presented in Table 1). The complete gene expression
analysis is presented in Supplementary Figure 5a and 6,
Supplementary Table 3 and 4 and in the Supplementary
Results.
The low cortisol concentration (100 nM) regulated 36
pathways (Po0.005). Of particular relevance is the activa-
tion of Notch- and Hairy/Enhancer of Split (Hes)-signaling,
which is crucially involved in changing neuronal- to
astroglial cell fate (Kageyama and Ohtsuka, 1999). Activa-
tion of this pathway may thus potentially be involved in the
above described MR-mediated shift from neurogenesis to
astrogliogenesis upon treatment with low cortisol concen-
trations in our experiments.
The high cortisol concentration (100 mM) regulated five
pathways (Po0.005), among which TGFb-SMAD2/3-signal-
ing was downregulated and FOXO3A signaling was acti-
vated (Table 1). Both pathways have been implicated in
neurogenesis, depression, and glucocorticoid action (Shull
et al, 1995; Graciarena et al, 2010; Seuntjens et al, 2009;
Musil et al, 2011), and their regulation is thus consistent
with decreased progenitor proliferation in our experiments.
However, opposite to the effect of the low concentration, the
high cortisol concentration decreased Notch/Hes-signaling
(at a lower significance level: P¼ 0.04). This could possibly
be explained by high cortisol concentrations predominantly
activating the GR, thereby inhibiting the MR-mediated
increase in these signaling pathways present with low
concentrations.
Finally, both low and high cortisol concentrations
significantly regulated seven pathways. Inhibition of Hedge-
hog signaling is thereby particularly relevant, because
Cortisol, MR, GR and neurogenesis
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Table 1 Pathways Regulated by Cortisol in Human Hippocampal Progenitor Cells
Pathways regulated by cortisol 100 nM
Pathway name Change P-value
Notch pathway þ 0.00003
VEGFR - ATF/CREB/ELK-SRF signaling  0.00004
ICAM1 - AP-1/CREB/ELK-SRF signaling þ 0.00005
EGFR/ERBB2- TP53 signaling þ 0.00006
EGFR/ERBB2 -4 HIF1A signaling þ 0.0001
ProstaglandinFR- ATF1/ELK-SRF/CREB signaling þ 0.0001
ThrombinR- AP-1/CREB/ELK-SRF/SP1 signaling þ 0.0001
EphrinR- actin signaling þ 0.0001
DopamineR2- AP-1/CREB/ELK-SRF signaling þ 0.0001
EndothelinRa- AP-1/CREB signaling þ 0.0001
VasopressinR1- CREB/ELK-SRF/AP-1/EGR signaling þ 0.0002
EGFR/ERBB2- CTNNB signaling  0.0002
Axon Guidance þ 0.0002
EndothelinRb- AP-1/CREB/ELK-SRF signaling þ 0.0002
EGFR - SMAD1 signaling þ 0.0003
EGFR/ERBB3- MEF/MYOD/NFATC/MYOG signaling þ 0.0003
Focal adhesion regulation þ 0.0005
EGFR - CTNND signaling  0.0006
ProstaglandinIR- ATF1/ELK-SRF/CREB signaling þ 0.0007
IL13R - STAT6 signaling þ 0.0008
ERBB2/3- EP300/ETS/ETV/SP1 signaling þ 0.0009
VasopressinR2- CREB/ELK-SRF/AP-1/EGR signaling þ 0.001
PTAFR - AP-1/ATF1/CREB/ERK-SRF signaling þ 0.001
Mast cell activation þ 0.001
B-cell activation þ 0.001
KIT- MITF signaling þ 0.002
Hairy, Hairy/E(SPL) signaling þ 0.002
FGFR - RUNX2 signaling þ 0.002
EDG3/5- AP-1/ELK-SRF signaling þ 0.002
IL4R - ELK-SRF/HMGY signaling þ 0.002
T-cell receptor - ATF/CREB signaling þ 0.002
CannabinoidR- AP-1/EGR signalingNK cell activation þ 0.002
NeurotensinR - ELK-SRF/AP-1/EGR signaling þ 0.003
MAP3K signaling þ 0.003
VasopressinR1- MEF/MYOD/NFATC/MYOG signaling þ 0.003
Actin cytoskeleton regulation þ 0.003
Pathways regulated by cortisol 100 lM
Pathway name Change P-value
T-cell activation þ 0.0001
TGFb receptor - SMAD2/3 signaling  0.001
GF signaling þ 0.002
GFR- FOXO3A signaling þ 0.002
Endocytosis þ 0.004
Pathways regulated by cortisol 100 nM and 100 lM
Pathway name Change P-value Corticosterone 100 nM P-value Corticosterone 100 lM
Hedgehog pathway  0.005 0.0002
GFR- NCOR2 signaling þ 0.0001 0.00008
GFR- AP-1/CREB/CREBBP/ELK-SRF/MYC signaling þ 0.0005 0.0006
Adherens junction regulation þ 0.003 0.0003
Guanylate cyclase pathway þ 0.004 0.0004
Apoptosis regulation þ 0.003 0.003
Gonadotrope cell activation þ 0.005 0.00003
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activation of this pathway promotes neuronal differentia-
tion (Ahn and Joyner, 2005; Cai et al, 2008), which, as
described above, is decreased upon treatment with low and
high cortisol concentrations in our experiments.
Stimulation of Hedgehog Signaling Counteracts Cortisol
Effects on Neurogenesis
In order to test the hypothesis that inhibition of Hedgehog
signaling is indeed part of the mechanism by which cortisol
decreases neurogenesis, we co-treated cells with cortisol and
with the smoothened (SMO)-agonist, purmorphamine,
which activates Hedgehog signaling (Sinha and Chen,
2006). As expected, purmorphamine (1 nM–1 mM) increased
neuronal differentiation into MAP2-positive neurons (One-
way ANOVA, P¼ 0.02, F1,4¼ 3.88, n¼ 3; Figure 3a) and into
Dcx-positive neuroblasts (One-way ANOVA, P¼ 0.13,
F1,4¼ 2, n¼ 3; t-test: veh vs Purmorphamine 1mM,
P¼ 0.03, n¼ 3; Figure 3b). Importantly, co-treatment with
the two lowest concentrations of purmorphamine, which do
not exert an effect on neuronal differentiation by themselves
(1 nM and 10 nM, see Figure 3a and b), counteracted the
decrease in MAP2- and Dcx-positive neurons upon treat-
ment with 100 nM (Figure 3c and d) and with 100 mM of
cortisol (Figure 3e and f). These data support the notion
that inhibition of Hedgehog signaling by cortisol significantly
contributes to the decrease in neuronal differentiation.
Regulation of Molecular Signaling Pathways in
Prenatally Stressed Rats
In order to compare our in vitro findings in human cells
with an in vivo model of stress-induced biological and
behavioral abnormalities, we conducted gene expression
microarray and pathway analysis in the hippocampus of
prenatally stressed (PNS) rats, a well established animal
model of depression in which hippocampal neurogenesis is
decreased (Lemaire et al, 2000; Pryce et al, 2011). Consistent
with the literature, adult PNS rats (PND 62) exhibited
significantly increased blood concentrations of CORT
(control: 226±66 ng/ml, n¼ 5; PNS: 437±82 ng/ml, n¼ 5;
P¼ 0.03). Again, here we present the results of the pathway
analysis (see Table 2), while the complete gene expression
analysis is presented in Supplementary Figure 7,
Supplementary Table 5 and in the Supplementary Results.
Importantly, we found that, among the eight pathways
regulated in the hippocampus of adult PNS rats (Po0.05),
TGFb-SMAD2/3- and Hedgehog signaling were both in-
hibited, which is the same effect that we observed in human
hippocampal progenitor cells treated with high, stress-
relevant concentrations of cortisol (described above).
qPCR Validation of Affymetrix Findings
To confirm the importance of Hedgehog signaling for
cortisol and stress effects, both in vitro and in vivo, we
analyzed expression of three key targets of Hedgehog
signaling by qPCR: the transcription factor, Gli, the
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Figure 3 Effects of purmorphamine on neurogenesis. Purmorphamine increases neuronal differentiation into microtubule-associated protein 2 (MAP2)-
positive neurons (a) and into doublecortin (Dcx)-positive neuroblasts (b). The decrease in MAP2- and Dcx-positive cells upon treatment with the low
cortisol concentration (100 nM) is counteracted by purmorphamine (10 nM) (c, d). The decrease in MAP2- and Dcx-positive cells upon treatment with the
high cortisol concentration (100 mM) is also counteracted by purmorphamine (10 nM) (e, f). Three independent experiments were conducted on
independent cultures (n¼ 3). Four wells were analyzed per treatment condition in each experiment and three random, non-overlapping pictures were
analyzed for each well. All data are mean±s.e.m. *Po0.05, compared with the vehicle-treated control condition or as indicated.
Table 2 Pathways Regulated by Prenatal Stress in the Rat
Hippocampus
Pathway name Change P-value
NF-kB signaling  0.018
TGFb Receptor- SMAD2/3-signaling  0.026
Insulin Action þ 0.034
Glycogen metabolism þ 0.037
Fatty acid oxidation þ 0.046
Hedgehog pathway  0.047
Leptin receptor- ELK–SRF signaling þ 0.049
ROS metabolism  0.049
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Hedgehog pathway activator, SMO, and the Hedgehog-
interacting protein, HHIP1. Both, in cortisol-treated hippo-
campal progenitor cells and in the hippocampus of adult
PNS rats, we found a significant reduction of Gli (CORT
100 nM: 0.66±0.08 fold, P¼ 0.02, n¼ 3, CORT 100 mM:
0.71±0.07 fold, P¼ 0.02, n¼ 3; PNS: 0.64±0.05 fold,
P¼ 0.006, n¼ 5) and SMO (CORT 100 nM: 0.76±0.04 fold,
P¼ 0.03, n¼ 3, CORT 100 mM: 0.55±0.1 fold, P¼ 0.04,
n¼ 3; PNS: 0.82±0.03, P¼ 0.002, n¼ 5), and an increase in
HHIP1, which inhibits Hedgehog signaling (CORT 100 nM:
1.9±0.24 fold, P¼ 0.03, n¼ 3, CORT 100 mM: 2.4±0.36
fold, P¼ 0.02, n¼ 3; PNS: 1.24±0.09 fold, P¼ 0.04, n¼ 5).
Together, these data confirm our finding that Hedgehog
signaling is decreased upon cortisol treatment in human
hippocampal progenitor cells and by PNS in the adult rat
hippocampus.
In addition, we further validated 10 of the most
significantly regulated genes with an absolute fold-change
of 41.3 fold for each cortisol concentration (100 nM and
100 mM) and for PNS rats (Supplementary Tables 1 and 2).
We found a high correlation of the fold-changes detected by
affymetrix and by qPCR (cortisol-treated progenitor cells:
Pearson’s correlation: r¼ 0.92, r2¼ 0.84, Po0.0001;
Supplementary Figure 5b; Hippocampi of adult PNS
rats: Pearson’s correlation: r¼ 0.995, r2¼ 0.99, Po0.001;
Supplementary Figure 5c).
DISCUSSION
Here, we identify for the first time the molecular signaling
pathways regulated by cortisol in human hippocampal
progenitor cells and by PNS in the adult rat hippocampus.
Firstly, we demonstrate that low and high cortisol
concentrations exert differential MR- and GR-dependent
effects on human hippocampal neurogenesis. We found that
low cortisol concentrations, by predominantly activating
the MR, increase progenitor cell proliferation and shift
neuronal development towards astrocyte development,
while high concentrations of cortisol, by predominantly
activating the GR, reduce both proliferation and neuronal
differentiation, and inhibit the MR-induced increase in
astrogliogenesis. At the molecular level, low cortisol
concentrations enhance Notch/Hes-signaling, high cortisol
concentrations inhibit TGFb-SMAD2/3-signaling, and both
concentrations inhibit Hedgehog signaling. We also demon-
strate that this inhibition of Hedgehog signaling is critically
involved in the cortisol-induced decrease in neurogenesis.
Secondly, and in line with the effects of high cortisol
concentrations on human hippocampal progenitor cells,
TGFb-SMAD2/3- and Hedgehog signaling are also down-
regulated in the hippocampus of adult prenatally stressed
rats with elevated glucocorticoid levels. We are confident
that these novel findings shed light on important molecular
mechanisms underlying stress-related disorders, such as
major depression.
The differential and common effects of MR- and GR-
activation on proliferation and neuronal differentiation
have never been shown in a human model, but have been
suggested by previous studies in rodents. For example, GR
activation by high glucocorticoid levels, as they occur upon
stress and in depression, consistently decreases hippocampal
cell proliferation and neuronal differentiation in vivo (Gould
et al, 1991; David et al, 2009; Mayer et al, 2006) and in vitro
(Kim et al, 2004; Yu et al., 2011). Importantly, GRþ / 
mice with a 50% gene dose reduction in the whole body,
and mice with a forebrain-specific deletion of the GR,
show stress hypersensitivity and reduced hippocampal
neurogenesis (Ridder et al, 2005; Kronenberg et al, 2009;
Boyle et al, 2006), possibly caused by impaired
hypothalamus–pituitary–adrenal (HPA) axis feedback
inhibition and subsequent hypercortisolemia, affecting the
hippocampus. Accordingly, mice overexpressing the GR
are stress-resistant (Ridder et al, 2005). Interestingly, GR
deletion in the entire nervous system causes increased
CORT levels but does not elicit decreased hippocampal
neurogenesis (Tronche et al, 1999; Gass et al, 2000).
In contrast to the GR, MR activation by aldosterone
increases hippocampal progenitor proliferation in adrena-
lectomized rats (Fischer et al, 2002), while MR knockout
decreases proliferation (Gass et al, 2000), and the MR
antagonist, spironolactone, increases neuronal differentia-
tion (Chang et al, 2008). These animal studies, together with
our human cellular data, therefore, support the notion that
MR- and GR-activation indeed exert opposite effects on
progenitor proliferation, while activation of both receptors
decreases neuronal differentiation.
Interestingly, we identified several relevant molecular
signaling mechanisms involved in the differential MR- and
GR-mediated effects of cortisol on hippocampal neurogen-
esis and astrogliogenesis. The low cortisol concentration
(100 nM) activates Notch-/Hes-signaling, which has been
shown by previous studies to increase progenitor prolifera-
tion and glia differentiation (Guo et al, 2009; Kageyama
et al, 1999), an effect that we indeed observe in our
experiments. In contrast, the high cortisol concentration
downregulates Notch/Hes-signaling, thereby potentially
inhibiting MR-mediated effects on proliferation and astro-
gliogenesis. Moreover, the high cortisol concentration
inhibits TGFb-SMAD2/3-signaling, which has previously
been shown to be decreased upon GR activation (Meisler
et al, 1995; Battista et al, 2006) and in depressed patients
(Musil et al, 2011). Furthermore, increased TGFb signaling
promotes neurogenesis in vitro and in vivo (Battista et al,
2006; Graciarena et al, 2010; Seuntjens et al, 2009),
suggesting that the cortisol-induced inhibition of this
pathway may potentially contribute to the GR-dependent
decrease in neurogenesis in our cellular model.
Finally, both low and high concentrations of cortisol
inhibit Hedgehog signaling. Hedgehog signaling promotes
neuronal differentiation (Ahn et al, 2005; Cai et al, 2008;
Kageyama et al, 1999) and inhibition of this pathway is
therefore in line with decreased neurogenesis upon treat-
ment with both low and high cortisol concentrations in our
study. Indeed, we demonstrate that stimulating Hedgehog
signaling with the pharmacological compound, purmorpha-
mine, counteracts the cortisol-induced decrease in neuro-
genesis, supporting the notion that inhibition of this
pathway may be significantly involved in the effects of
cortisol on neurogenesis.
Importantly, in our experiments TGFb-SMAD2/3- and
Hedgehog signaling are also downregulated in the hippo-
campus of adult rats with increased blood glucocorticoid
levels as a result of PNS, an established animal model of
Cortisol, MR, GR and neurogenesis
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depression (Fumagalli et al, 2007). This is the same effect
that we observed in our cellular model upon treatment with
high (stress-relevant) concentrations of cortisol, again
indicating that common signaling pathways may be
particularly relevant for stress- and glucocorticoid effects
on the hippocampus, both in human cells and in rodent
tissue. Indeed we found that three key targets of Hedgehog
signaling—the transcription factor, Gli, the Hedgehog
receptor, SMO, and the Hedgehog inhibitor, HHIP1—are
regulated exactly in the same way by cortisol in vitro and by
PNS in vivo. It is noteworthy, however, that despite these
striking similarities, we have also found pathways and genes
that were regulated differently by high cortisol concentra-
tions in vitro and by stress in vivo, most likely due to the
fact that the majority of cells in the hippocampus are
neurons and glia cells, while progenitor cells only comprise
a very small portion of the hippocampus. Accordingly,
previous gene expression studies upon cortisol treatment in
other cell types or tissues, such as fibroblasts, pre-
adipocytes or fetal whole brain tissue, have found some
similarities in gene expression when compared with our
study, probably because cortisol was used as a common
stimulus; but they also found many differences, likely due to
tissue-specific effects of glucocorticoids (Smith et al., 2008;
Bujalska et al, 2006; Salaria et al, 2006). In particular,
cortisol-induced changes in Hedgehog signaling were not
detected by these studies on other cell types, supporting the
notion that the regulation of Hedgehog signaling may
indeed be most relevant for the hippocampus and for
hippocampal progenitor cells.
Are our findings relevant to the understanding of
depression pathogenesis? Post-mortem studies have con-
firmed that patients with major depression—a condition
often characterized by elevated glucocorticoids—show
reduced hippocampal neurogenesis, while antidepressants
reverse or prevent this effect (Boldrini et al, 2009, 2012;
Lucassen et al, 2010). Moreover, we have shown that
antidepressants reduce glucocorticoid actions in vitro using
human hippocampal progenitor cells (Anacker et al, 2011b),
as well as in vivo using electroencephalography (Pariante
et al., 2011) and neuroendocrine tests (Pariante, 2003).
Therefore, the prevailing model suggests that excessive MR-
and GR-stimulation by hypercortisolemia reduces neuro-
genesis in the hippocampus of depressed patients, which
can be rescued by effective antidepressant treatment. It is,
however, important to emphasize that the ‘neurogenesis
hypothesis’ of depression is not universally accepted. For
example, some studies have questioned a potential func-
tional role for hippocampal neurogenesis, because relatively
few new neurons are being added to the adult brain (Rakic
1985). Furthermore, one human post-mortem brain study
did not find any changes in hippocampal cell proliferation
in depressed patients, although the study sample was
heterogeneous and comprised depressed and antidepres-
sant-treated patients (Reif et al, 2006). Moreover, rodent
studies have suggested that reduced neurogenesis per se
may indeed not contribute to the development of depres-
sion, while being critical for the effects of antidepressants
(Santarelli et al, 2003; Surget et al, 2008). However, more
recent studies have demonstrated that neurogenesis sig-
nificantly contributes to the regulation of the HPA axis and
depressive behavior in rodents (Snyder et al, 2011; Surget
et al, 2011), suggesting that reduced neurogenesis may
impair hippocampal inhibitory control over the HPA axis
during stress, subsequently causing sustained hypercorti-
solemia and depressive symptoms (Anacker and Pariante
2012).
A possible limitation of our in vitro model is that the
immortalized human fetal hippocampal progenitor cells,
while being invaluable for our understanding of the
molecular mechanisms in the human hippocampus, may
differ from the situation in a adult organism in vivo.
Moreover, the cortisol concentrations used in our in vitro
experiments are likely higher than the so far unknown
physiological concentrations in the brain of stressed or
depressed humans. It is important to emphasize that the
differences between the in vivo cortisol and in vitro CORT
concentrations in our study may be explained by the high
abundance of albumin in the cell culture media and the
reportedly high expression of 11b-hydroxysteroid dehydro-
genase 2 and multidrug-resistant p-glycoprotein in fetal
tissue and stem cells (Brown et al, 1996; Islam et al, 2005,
Lin et al, 2006). These factors likely diminish cortisol
bioavailability in our progenitor cell system, thereby
making potentially higher concentrations necessary to
specifically activate corticosteroid receptors. Indeed, our
dose–response study of GR activation shows that the GR is
not saturated at the high cortisol concentration (100 mM). A
further clear limitation of the in vitro model employed in
this study is that no data is yet available on electrophysio-
logical properties of differentiated HPC03A/07 cells. It will
thus be an important line of future investigation to examine
whether HPC03A/07 cells develop electrophysiological
properties of functionally mature neurons, in order to fully
characterize the potential impact of this cellular model for
functional neuronal network properties and human neuro-
genesis in vitro.
In conclusion, our data shed light on the effects of cortisol
on human hippocampal neurogenesis and astrogliogenesis,
and identify novel molecular signaling pathways involved in
the effects of glucocorticoids and stress on the hippo-
campus. Targeting these pathways may provide future treat-
ment strategies to counteract cortisol-induced impairments
in hippocampal plasticity in depressed patients.
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